We are developing two product candidates targeting PCSK9 – VERVE-101 and VERVE-102. These single-course treatments are designed to permanently turn off the PCSK9 gene in the liver to reduce disease-driving LDL-C.
https://www.vervetx.com/our-programs/verve-101-102
https://www.vervetx.com/our-programs/our-pipeline
Ultimately, we plan to further expand to all adults at risk for ASCVD in the general population as a preventative measure.
A single dose of Lilly’s PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
In the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 produced dose-dependent lowering of PCSK9 and LDL-C, with both reductions sustained over follow-up of up to 18 months in participants at high risk for cardiovascular disease
VERVE-102 is designed to mimic the protective effect of naturally occurring loss-of-function variants in PCSK9, which are associated with markedly lower lifetime risk of coronary heart disease
Lilly plans to begin enrolling the Phase 2 clinical study of VERVE-102 by the end of this year
(post deleted by author)
What’s your take? @adssx Given that this permanently knocks out the PCSK9 gene in the liver, would you jump on it as soon as it hits the market, or would you wait decades to make sure it’s absolutely safe? Let me know what you think.
Personally, I’d wait a few years after launch for some solid follow-up studies to come out before making a decision. Since I don’t even have lipid issues to begin with, I’d want to give it time to prove its long-term safety and rule out any off-target effects.
